Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
J Thromb Haemost. 2010 Jan;8(1):90-4. doi: 10.1111/j.1538-7836.2009.03676.x. Epub 2009 Oct 30.
Initiation of warfarin therapy is complicated by its narrow therapeutic index and inter-patient dose-effect variability. A '10-mg nomogram' warfarin initiation protocol permits safe therapeutic anticoagulation in outpatients started on warfarin. We aimed to develop a safe and effective warfarin maintenance dose prediction tool in these patients.
Baseline potential predictor variables were collected on a retrospective cohort of outpatients initiated on warfarin for venous thromboembolism treatment. The primary outcome was the warfarin maintenance dose, defined as mean warfarin dose over the last 10 days of the first month of warfarin treatment. Univariate and multivariate analyses were performed to determine which baseline variables were warfarin maintenance dose predictors. An independent cohort of patients validated the derived warfarin maintenance dose prediction rule.
Patient's age and weight, cumulative dose of warfarin over the first week of induction and international normalized ratio (INR) on days 3, 5 and 8 were statistically significant predictors of the warfarin maintenance dose. Our final prediction rule reads: maintenance dose (in mg) = 2.5 + 10% of the first week cumulative dose - INR value at day 8 + 1.5 if INR was below 2.0 at day 5. In the validation cohort, the predicted dose was strongly correlated with the actual maintenance dose (r = 0.88, P < 0.0001). The mean difference between observed and predicted dose was not clinically significant: -0.1 +/- 1.1 mg.
In outpatients initiated on warfarin using a '10-mg nomogram', a simple prediction rule can accurately predict warfarin maintenance dose. Prospective studies employing the rule are indicated.
华法林治疗的启动较为复杂,因其治疗指数较窄和患者间剂量效应差异较大。“10mg 图表法”华法林起始治疗方案可用于安全抗凝治疗门诊接受华法林治疗的患者。我们旨在为这些患者开发一种安全有效的华法林维持剂量预测工具。
回顾性收集接受华法林治疗静脉血栓栓塞症的门诊患者的基线潜在预测变量。主要结局是华法林维持剂量,定义为华法林治疗第一个月的最后 10 天的平均华法林剂量。进行单变量和多变量分析以确定哪些基线变量是华法林维持剂量的预测因子。验证队列中的独立患者验证了所得华法林维持剂量预测规则。
患者的年龄和体重、诱导治疗第一周的累积华法林剂量以及 INR 值在第 3、5 和 8 天是华法林维持剂量的统计学显著预测因子。我们的最终预测规则为:维持剂量(mg)= 2.5 + 第一周累积剂量的 10% - INR 值在第 8 天 + INR 值在第 5 天低于 2.0 时加 1.5。在验证队列中,预测剂量与实际维持剂量具有很强的相关性(r = 0.88,P <0.0001)。观察剂量与预测剂量之间的平均差异无临床意义:-0.1 +/- 1.1mg。
在使用“10mg 图表法”启动华法林治疗的门诊患者中,简单的预测规则可准确预测华法林维持剂量。需要进行前瞻性研究来验证该规则。